For the Inventor, By the Inventor

Enter assignee name

New York, NY, United States of America

Anavex Life Sciences Corp.

USPTO Granted Patents = 33

CIPO Patents = 3

EPO Patents = 6

Trademarks = 3

Forward Citations = 29

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Christopher U Missling (23 out of 24 patents)

Alani Selvey (5 out of 5 patents)

Daniel Mark Ledger (4 out of 7 patents)

4. Linda Sharon Daintree (4 out of 8 patents)

5. Lucy Anne Leonard (4 out of 4 patents)

6. Peter York (4 out of 7 patents)

7. Marco Cecchi (2 out of 2 patents)

8. Cameron Durrant (2 out of 3 patents)

9. Alexandre Vamvakides (2 out of 2 patents)

10. Missling U Christopher (1 out of 1 patent)

11. Durrant Cameron (1 out of 1 patent)

12. Tangui Maurice (1 out of 1 patent)

13. Gervais Neliat (1 out of 1 patent)

14. Mohammad Michel Afshar (1 out of 1 patent)

15. Frédéric Parmentier (1 out of 1 patent)

Core Competencies:

Neurodevelopmental Disorder Therapy

Sigma-1 Agonist

A2-73

Alzheimer's Disease

Anticholinesterase Inhibitors

Insomnia Treatment

Anxiety Therapy

Cardiac Dysfunction

Anti-Seizure Therapy

Crystalline Polymorphs

Analgesic Therapeutics

Cytoprotective Properties

33 patents: Sort by Forward Citations

1. 12759986 - Crystal forms of tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanmethanamine, processes of making such forms, and their pharmaceutical compositions (2026-10-13),

2. 12734147 - Neurodevelopmental disorder therapy (2026-09-15),

3. 12642784 - ANAVEX2-73 for the treatment of genetic neurodevelopmental disorders (2026-06-02),

4. 12594256 - A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy (2026-04-07),

5. 12558340 - ANAVEX2-73 for the treatment of genetic neurodevelopmental disorders (2026-02-24),

6. 12533352 - Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof (2026-01-27),

7. 12383526 - Optimized sigma-1 agonist method of responder selection and treatment (2025-08-12),

8. 12285403 - A2-73 as a therapeutic for insomnia, anxiety and agitation (2025-04-29),

9. 12280034 - Sigma-1 receptor agonist systolic blood pressure therapy (2025-04-21),

10. 12208079 - Enantiomers of A2-73, analogues, and sigma agonist activity (2025-01-28),

11. 12180174 - A2-73 crystalline polymorph compositions of matter and methods of use thereof (2024-12-31),

12. 12138240 - Treatment of cardiac dysfunction (2024-11-12),

13. 11896590 - Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof (2024-02-13),

14. 11839600 - Neurodevelopmental disorder therapy (2023-12-12),

15. 11813242 - A2-73 as a therapeutic for insomnia, anxiety, and agitation (2023-11-14),

Company Overview

Anavex Life Sciences Corp. is a biopharmaceutical company based in New York, specializing in the development of innovative therapies for neurodegenerative diseases and other central nervous system disorders. The company focuses on advancing its proprietary drug candidates through clinical trials, aiming to address unmet medical needs in conditions such as Alzheimer's disease and other related disorders. Anavex is committed to leveraging its research capabilities to enhance patient outcomes and improve quality of life.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

33 Patents

#270 in New York, NY

#623 in New York

#10,305 in US

#20,147 in the World

New York, NY, United States of America

Anavex Life Sciences Corp.

Forward Citations = 29

15 inventors:

Christopher U Missling (23 out of 24 patents)

Alani Selvey (5 out of 5 patents)

Daniel Mark Ledger (4 out of 7 patents)

4. Linda Sharon Daintree (4 out of 8 patents)

5. Lucy Anne Leonard (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Anavex Life Sciences Corp.. Retrieved from https://idiyas.com/company/anavex-life-sciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…